CONFERENNE ABSTRACT

Prognostic significance of CXCR4 and mTOR expression in diffuse large B-cell lymphoma patients

Rasha Haggag*, Naglaa A. Mostafa, Marwa Nabil, Hala A. Shokralla, Neveen F. H. Sidhom

1 Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3 Medical Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt
4 Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt

Received: January 9, 2019 Accepted: January 10, 2019 Online Published: January 16, 2018
DOI: 10.5430/jst.v9n1p7 URL: https://doi.org/10.5430/jst.v9n1p7

ABSTRACT

Background: The aim of this study was to investigate the prognostic role of mammalian target of rapamycin (mTOR) and C-X-C chemokine receptor type 4 (CXCR4) in diffuse large-B-cell lymphoma (DLBCL) patients.

Patients and methods: This retrospective study was collected data from 64 de novo DLBCL patients, who received standardized R-CHOP therapy at two oncology centers. CXCR4 and mTOR expressions were assessed by immunohistochemistry.

Results: Out of the 64 DLBCL patients, 40 patients were positive for CXCR4 (62.5%) and 35 patients for mTOR (54.7%) expressions. CXCR4 expression was positively correlated with mTOR expression ($r = 0.7; p < .001$). While mTOR expression was significantly associated with high lactate dehydrogenase level ($p = .03$) and number of extranodal sites one or more ($p = .02$), CXCR4 expression was significantly associated with high IPI score ($p < .001$) and ECOG PS ($p = .005$). Furthermore, the expression levels of mTOR and CXCR4 were significantly associated with older ages and poor response to treatment ($p = .04, < .001$ and $.04, .03$, respectively). After a median Follow up of 22 months, mean ± SD overall survival (OS) was $65.391 ± 4.705$. Kaplan–Meier analysis showed that patients positive for mTOR and CXCR4 expression had shorter DFS ($p = .01, .02$) and OS ($p = .02, .04$). Multivariate analysis showed that CXCR4 and mTOR positivity is an independent prognostic factor for significantly poorer DFS ($p = .03, .02$) but not for OS ($p = .09, .08$) in the DLBCL patients.

Conclusion: Our results indicate that the expression of CXCR4 and mTOR may be poor prognostic biomarkers in DLBCL.

Key Words: DLBCL, Mammalian target of rapamycin, CXCR4, Immunohistochemistry, Prognosis

*Correspondence: Rasha Haggag; Email: rashaoncology@gmail.com; Address: Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt.